Hims & Hers Health (HIMS): A Powerful Growth Company — But Is the Stock Cheap Enough?

Executive Summary

Hims & Hers Health has evolved far beyond the company that originally sold hair-loss and erectile-dysfunction treatments online.

It is increasingly trying to become something much bigger: a consumer healthcare platform where patients can obtain diagnosis, prescriptions, medications, laboratory testing, ongoing care, weight-loss treatment and increasingly AI-assisted personalized healthcare—all without going through the traditional doctor’s-office system.

And the growth has been extraordinary.

Hims & Hers generated $2.35 billion of revenue in 2025, up 59%, and in the second quarter of 2026 revenue reached $753 million, up another 38% year over year. Subscribers increased 19% to almost 2.9 million, while monthly revenue per average subscriber climbed 21% to $92. Management now expects $3.1-$3.3 billion of revenue in 2026 and continues to target at least $6.5 billion of revenue and $1.3 billion of adjusted EBITDA by 2030. (Hims)

That makes HIMS one of the fastest-growing sizable companies in digital healthcare.

But there is an important distinction between:

a great company

and

a great stock at a particular price.

At the August 28, 2026 closing price of $28.84, HIMS had a market capitalization of approximately $6.73 billion. Because trailing twelve-month earnings are currently negative, HIMS doesn’t have a meaningful trailing P/E. Its estimated forward P/E is about 74×. (StockAnalysis.com)

Therefore my overall conclusion is:

HIMS appears to be the best growth story among the public companies in this comparison, and perhaps the company with the greatest potential to build a consumer healthcare brand. But HIMS is not currently the cheapest or lowest-risk investment.

I would characterize it as a growth investment at a somewhat demanding valuation, rather than a classic value investment.

1. What Exactly Is Hims & Hers?

The easiest mistake investors can make with HIMS is thinking it is simply an online pharmacy.

It isn’t.

Hims & Hers combines several businesses:

  • consumer healthcare branding
  • telehealth consultations
  • prescription services
  • subscription healthcare
  • pharmacies
  • personalized/compounded medications
  • weight management
  • sexual health
  • dermatology
  • hair loss
  • mental health
  • hormone health
  • laboratory testing
  • mobile healthcare applications
  • AI-assisted healthcare
  • international digital healthcare

The platform connects patients with healthcare professionals, handles prescriptions and in many cases fulfills the prescriptions through Hims-owned pharmacies.

That vertical integration matters.

Hims operates its own pharmacy infrastructure and says the majority of prescriptions are fulfilled through wholly owned pharmacies. Its platform integrates providers, electronic medical records, prescribing, pharmacy fulfillment and personalization. (SEC)

This is considerably more sophisticated than merely operating a website that refers customers to doctors.

2. The Growth Story Is Excellent

The numbers explain why investors became excited about HIMS.

2025

Revenue:

$2.35 billion

Growth:

+59%

Subscribers:

2.51 million

Subscriber growth:

+13%

Monthly revenue per subscriber:

$83, up 28%

Adjusted EBITDA:

$318 million (SEC)

Then came Q2 2026.

Revenue reached:

$753.2 million

Growth:

+38%

Subscribers:

2.89 million

Growth:

+19%

Monthly revenue per average subscriber:

$92

Growth:

+21% (Hims)

There is something particularly attractive about the last number.

HIMS isn’t merely adding customers.

It is getting more revenue from each customer.

That suggests cross-selling and personalization are working.

3. HIMS Has Discovered the Healthcare Equivalent of Cross-Selling

Imagine someone originally joins HIMS for hair loss.

Eventually the same person might use HIMS for:

hair loss → sexual health → weight management → testosterone → lab tests → cardiovascular health.

The cost of acquiring that customer was incurred initially.

Each additional treatment potentially increases the customer’s lifetime value without requiring HIMS to acquire an entirely new person.

That is one reason personalization is so important.

In 2025, personalized offerings accounted for more than 70% of U.S. revenue, compared with approximately half the previous year.

Hers has also become increasingly important. The Hers brand represented nearly 40% of U.S. revenue in 2025, compared with less than 30% in 2024. Importantly, a majority of U.S. revenue still came from non-GLP-1 products, so HIMS is not simply a weight-loss-drug company. (SEC)

That diversification is reassuring.

4. The Competitive Advantage

I see six important advantages.

1. Brand

Healthcare is unusually sensitive to branding and trust.

Conditions such as:

  • erectile dysfunction
  • hair loss
  • obesity
  • menopause
  • testosterone
  • mental health

can be embarrassing or inconvenient to discuss in a traditional setting.

Hims and Hers created consumer-friendly brands around these conditions.

That brand recognition gives HIMS a customer-acquisition advantage that a small telehealth startup cannot reproduce overnight.

2. Vertical Integration

HIMS increasingly controls the healthcare supply chain itself.

It has invested in pharmacies, fulfillment, laboratories, manufacturing capabilities and software rather than simply outsourcing everything.

This potentially provides:

lower cost + faster delivery + better personalization + more control over customer experience.

The company says the majority of its prescriptions are already fulfilled through company-owned pharmacies. (SEC)

This is probably one of HIMS’ strongest competitive advantages.

3. Subscription Economics

Healthcare naturally contains many recurring conditions.

Hair loss doesn’t disappear after one month.

Neither does obesity, hypertension, sexual health treatment or many dermatological conditions.

That makes subscription healthcare structurally attractive.

Recurring relationships create predictable revenue while giving HIMS additional opportunities to sell other services.

4. Personalization

This may eventually become HIMS’ most important differentiator.

Rather than merely selling standard medications, HIMS wants treatment increasingly customized around the individual.

More than 70% of U.S. revenue was already associated with personalized offerings in 2025. (SEC)

Personalization potentially makes the customer relationship stickier than simply ordering a prescription from the cheapest online pharmacy.

5. The AI Opportunity Could Be Significant

HIMS is also trying to combine healthcare records, treatments, patient behavior and AI.

In August 2026, the company introduced a redesigned Hers application integrating patients, care teams, healthcare providers and AI within the same experience, initially focusing on weight-loss patients. (Hims)

Think about where this could eventually lead.

Instead of an AI chatbot merely saying:

“Talk to your doctor.”

a healthcare AI might know:

  • your medication
  • your weight
  • your laboratory history
  • your treatment response
  • your medical goals
  • your side effects
  • your previous physician interactions

and provide information to the medical team managing your treatment.

If executed safely and correctly, HIMS could gradually create a powerful health-data flywheel.

More patients generate more data.

More data improves personalization.

Better personalization potentially improves results.

Better results improve retention.

Higher retention generates more data.

That could become a real competitive advantage.

But healthcare AI brings considerable regulatory and liability risk, so this opportunity should not yet be treated as an established moat.

6. International Expansion

HIMS is no longer exclusively an American story.

In June 2026 it completed the acquisition of Eucalyptus, extending its presence across markets including Australia, Canada, Germany, Japan and the United Kingdom. Previous acquisitions had already expanded HIMS internationally.

The Eucalyptus transaction could eventually prove strategically brilliant.

But it wasn’t cheap.

HIMS agreed to consideration of up to $1.15 billion, including deferred payments and possible earnouts. (SEC)

And HIMS issued $402.5 million of 0% convertible senior notes due 2032 in May 2026. (SEC)

Therefore international expansion increases both:

potential return

and

execution risk.

7. The Problem Investors Shouldn’t Ignore: Margins

The Q2 2026 headline growth was excellent.

The profitability numbers weren’t.

Gross margin declined from:

76% → 64%.

Adjusted EBITDA declined:

$82.2 million → $60.3 million.

HIMS recorded a:

$86.3 million net loss.

Free cash flow was:

negative $68.2 million. (Hims)

Part of this reflects the changing weight-loss business, international expansion and acquisitions.

Nevertheless, investors need to watch this carefully.

HIMS’ long-term thesis doesn’t merely require revenue growth.

It requires:

rapid revenue growth today + substantial margin expansion later.

Management’s 2030 target calls for at least $6.5 billion of revenue and $1.3 billion of adjusted EBITDA, roughly a 20% adjusted EBITDA margin.

The 2026 guidance implies only around a 9%-10% adjusted EBITDA margin. (Hims)

There is therefore considerable execution embedded in that 2030 goal.

8. HIMS Versus Its Public Competitors

None of these businesses is perfectly comparable.

Ro, for example, is probably one of HIMS’ closest direct competitors but remains private, so there is no meaningful public P/E comparison.

Doximity operates primarily around healthcare professionals rather than direct-to-consumer treatment.

GoodRx is primarily medication affordability and distribution.

Teladoc has a large enterprise healthcare operation.

LifeMD is closer to HIMS operationally but dramatically smaller.

Nevertheless, comparing them is useful.

Company Latest growth picture Profitability Forward P/E* My interpretation
HIMS Q2 revenue +38% Q2 net loss; Adj. EBITDA positive ~74× Best growth; expensive
Doximity (DOCS) Revenue +7% Highly profitable ~18.8× Much slower but higher-quality earnings
GoodRx (GDRX) Revenue -1% Profitable ~32.7× Cheap relative to HIMS but weak overall growth
Teladoc (TDOC) Revenue -4% Net loss N/M Turnaround situation
LifeMD (LFMD) Q2 revenue declined Loss-making ~86.5× Smaller and more speculative

*Market valuation data as of August 28, 2026. (Hims)

9. HIMS Versus Doximity

Doximity is actually the company that makes the HIMS valuation look most uncomfortable.

Doximity recently reported:

Revenue growth:

7%

Net margin:

15.5%

Adjusted EBITDA margin:

47.7%

Free cash flow:

$39.6 million in the quarter. (Doximity)

And yet DOCS trades around:

31.7× trailing earnings

and only:

18.8× forward earnings. (StockAnalysis.com)

HIMS’ estimated forward multiple is approximately:

74×.

So HIMS clearly does not win on P/E.

However, there is another interesting valuation metric.

Doximity trades around 7.3× sales, whereas HIMS trades around 2.6× sales. (StockAnalysis.com)

Why?

Because Doximity converts an enormous percentage of revenue into cash.

HIMS doesn’t—at least not yet.

Therefore:

HIMS looks inexpensive on revenue but expensive on earnings.

That’s exactly what one would expect from a rapidly growing company whose margins have not matured.

10. HIMS Versus GoodRx

GoodRx is much cheaper on cash flow.

At approximately $3.53, GoodRx traded around:

32.7× forward earnings

1.5× sales

and roughly

6× free cash flow. (StockAnalysis.com)

Those numbers look dramatically cheaper than HIMS.

But there is a reason.

GoodRx Q2 revenue actually declined approximately 1%.

Its traditional prescription-transactions business declined substantially, although newer Pharma Direct and subscription businesses are growing rapidly. (GoodRx)

So the choice is essentially:

GoodRx = cheaper + profitable + slower

versus

HIMS = more expensive + faster growth + larger future opportunity.

For a value investor, GoodRx deserves consideration.

For a growth investor, I prefer the HIMS business.

11. HIMS Versus Teladoc

Teladoc is extremely inexpensive based on revenue.

At $6.50 it had a market capitalization around $1.18 billion and traded around only 0.47× sales. (StockAnalysis.com)

But once again, cheapness exists for a reason.

Q2 2026 Teladoc revenue declined 4%, BetterHelp revenue declined 12%, and the company remained unprofitable.

Teladoc therefore looks more like a turnaround.

HIMS looks like a growth company.

Even though HIMS is considerably more expensive, I would consider HIMS the higher-quality growth business of the two.

12. HIMS Versus LifeMD

LifeMD is probably more directly comparable.

It also offers direct-to-consumer healthcare and weight management.

But the scale difference is enormous.

Q2 LifeMD revenue was approximately:

$47.3 million

versus HIMS:

$753.2 million.

LifeMD’s Q2 revenue actually declined from $49 million, while adjusted EBITDA was negative approximately $3.5 million. (Nasdaq)

LifeMD has approximately 356,000 active subscribers versus almost 2.9 million for HIMS.

And LFMD’s forward P/E estimate is around 86× despite its smaller scale and greater execution risk. (StockAnalysis.com)

Between the two, I strongly prefer HIMS from a business-quality perspective.

13. Who Really Threatens HIMS?

The most dangerous competitors may ultimately not be Teladoc or LifeMD.

They may be:

Amazon

Amazon can combine healthcare, Prime, pharmacy fulfillment, enormous consumer distribution and logistics.

Pharmaceutical companies

Novo Nordisk and Eli Lilly increasingly have reasons to establish direct relationships with patients.

Why pay HIMS a piece of the economics if pharmaceutical manufacturers can reach consumers themselves?

Ro

Ro is probably one of the closest direct competitors in terms of online consumer healthcare and weight management.

Traditional healthcare

Insurance companies, physicians and pharmacy chains aren’t disappearing.

HIMS therefore does not possess a traditional monopoly-like moat.

Switching costs for consumers remain fairly low.

14. How Strong Is the Moat?

I would grade the HIMS competitive advantage:

B+

The moat comes from the combination of:

Brand + customer acquisition + recurring subscriptions + pharmacy infrastructure + personalization + data + cross-selling + international scale.

That is meaningful.

But it isn’t equivalent to Microsoft’s operating-system ecosystem or Visa’s payment network.

Customers can still leave.

Competitors can copy individual treatments.

Drug manufacturers control many of the important medications.

HIMS must therefore continue innovating and marketing heavily.

I would call it an:

execution moat rather than an unassailable structural moat.

15. The GLP-1 Issue Is the Biggest Warning Sign

This is one area where investors should be particularly careful.

During the GLP-1 boom, HIMS aggressively expanded compounded semaglutide offerings.

In September 2025, the FDA sent CEO Andrew Dudum a warning letter stating that certain claims concerning Hims & Hers’ compounded semaglutide products were false or misleading, including implications that compounded products were equivalent to FDA-approved products. (U.S. Food and Drug Administration)

HIMS subsequently changed strategy.

In March 2026 it announced that its U.S. weight-loss offering would increasingly emphasize FDA-approved medications, including products from Novo Nordisk, while limiting compounded semaglutide.

That pivot was strategically sensible.

But the episode matters when evaluating management.

It demonstrates that Dudum is willing to move extremely aggressively.

That trait can produce extraordinary growth.

It can also produce regulatory problems.

16. CEO Andrew Dudum

Andrew Dudum is the co-founder of Hims & Hers and has served as CEO since its founding.

Before HIMS, he co-founded startup studio and investment fund Atomic Labs and participated in developing numerous startup businesses.

He earned a degree in Management and Economics from Wharton. (Hims)

He is still only in his late 30s, making the scale HIMS has achieved particularly impressive.

Let’s evaluate him using the three qualities you mentioned:

Integrity

Intelligence

Energy

17. Intelligence — 9/10

I consider the evidence for Dudum’s intelligence quite strong.

Look at what HIMS has accomplished.

It started with a handful of relatively simple healthcare problems.

It then expanded logically:

Hair loss
↓
Sexual health
↓
Dermatology
↓
Mental health
↓
Women’s health
↓
Weight management
↓
Hormonal health
↓
Lab testing
↓
International healthcare
↓
AI-powered personalized healthcare

That progression demonstrates strategic thinking.

The particularly clever part has been building infrastructure underneath the brand.

Instead of permanently depending on external pharmacies and technology vendors, HIMS has gradually vertically integrated.

The company then uses the same infrastructure to launch additional medical specialties.

That’s an intelligent scaling model.

Going from approximately $872 million of revenue in 2023 to $2.35 billion in 2025 is substantial evidence of managerial execution. (SEC)

My assessment:

Intelligence: 9/10

18. Energy — 9.5/10

There is very little doubt about Dudum’s energy.

In a remarkably short period HIMS has simultaneously pursued:

  • new medical specialties
  • pharmacies
  • laboratories
  • personalized medicine
  • GLP-1s
  • international expansion
  • acquisitions
  • AI
  • mobile healthcare
  • manufacturing infrastructure

The Eucalyptus acquisition alone substantially expanded the company’s geographic footprint.

This is not a management team behaving conservatively.

Dudum clearly wants to build a very large company.

My assessment:

Energy: 9.5/10

But excessive energy has another name:

overexpansion.

That is something shareholders should watch.

19. Integrity — More Complicated

Integrity is much harder to measure from outside a company.

I don’t think investors should label a CEO honest or dishonest simply because a stock performs well or badly.

There are positive governance signals.

Dudum owns substantial equity.

His compensation is heavily equity-based.

The company maintains stock-ownership requirements and a clawback policy for certain incentive compensation. (SEC)

But I would not ignore the FDA episode.

The FDA specifically told Dudum in September 2025 that certain claims made regarding compounded semaglutide were false or misleading. (U.S. Food and Drug Administration)

I don’t have evidence from that alone to conclude Dudum personally intended to deceive customers.

But it is a legitimate blemish on the company’s compliance record and suggests management’s aggressive culture occasionally runs too close to regulatory boundaries.

The subsequent move toward FDA-approved GLP-1 medications was the responsible strategic response.

My assessment:

Integrity / governance judgment: roughly 7/10

I would describe the evidence as:

generally positive alignment, but with a meaningful regulatory yellow flag rather than a spotless record.

20. Does Andrew Dudum Have Skin in the Game?

Absolutely.

This is one of the strongest parts of the HIMS investment thesis.

As of April 16, 2026, the proxy reported Dudum beneficially owning:

15.39 million Class A shares

plus

8.38 million Class V shares. (SEC)

Some of that beneficial ownership consists of stock options or restricted shares. The proxy breaks it down as approximately:

  • 887,684 Class A shares directly
  • 8.64 million Class A shares through affiliated trusts
  • 8.38 million Class V shares through affiliated trusts
  • roughly 155,000 restricted shares vesting within 60 days
  • about 5.71 million options exercisable within 60 days (SEC)

So this is unquestionably a founder with substantial economic exposure to the company.

I like that.

21. But There Is a Governance Catch

Dudum doesn’t merely own stock.

He effectively controls the company.

His Class V shares carry:

175 votes per share

versus one vote for Class A shares.

His beneficial ownership therefore represented approximately:

87.73% of HIMS’ total voting power

as of April 2026. (SEC)

This creates an unusual situation.

Positive

Dudum can think long term without worrying constantly about short-term activist shareholders.

Negative

Ordinary shareholders have very little ability to overrule him.

So skin in the game is excellent.

But corporate governance is much weaker from the perspective of minority shareholders.

I would score:

Founder alignment: A

Shareholder democracy: C

22. How Is Dudum Paid?

This is another area I actually like.

His 2025 base salary was:

$625,000. (SEC)

That isn’t the primary compensation.

His annual target cash bonus was equal to 100% of salary.

The bonus depended substantially upon HIMS achieving revenue and adjusted EBITDA targets.

For 2025 the compensation committee determined performance at 93.72% of target, resulting in Dudum receiving:

$585,763. (SEC)

This is sensible.

It links his cash bonus to:

growth + profitability.

23. The CEO Stock-Option Plan Is More Interesting

In 2025 Dudum received a performance stock-option award.

At target performance:

557,244 options

Maximum performance:

1,393,110 options

Exercise price:

$34.71 per share

The options depend on HIMS achieving revenue and adjusted EBITDA objectives for fiscal 2027, along with continued service. (SEC)

Notice something important.

The current HIMS stock price is:

$28.84.

The exercise price is:

$34.71.

Those performance options aren’t particularly valuable unless the company performs and the stock ultimately rises substantially above the exercise price.

That is alignment I prefer to an executive simply receiving enormous amounts of cash.

He also received 306,406 RSUs in 2025. (SEC)

24. His Compensation Is Still Very Large

There is a counterargument.

Dudum’s reported 2025 compensation was approximately:

$22.96 million

including approximately:

  • $10.64 million reported value of stock awards
  • $11 million reported value of option awards
  • $585,763 annual incentive compensation

among other items. (SEC)

Those equity award numbers are accounting grant-date values rather than a $22.96 million cash paycheck.

Still, it is substantial compensation.

The positive is that most of the value comes from equity rather than salary.

Additionally, shareholders gave the executive compensation program 98% approval in the company’s 2025 advisory vote. (SEC)

25. CEO Scorecard

Quality Rating Reason
Intelligence 9/10 Excellent platform strategy, vertical integration and scaling
Energy 9.5/10 Extremely aggressive product and geographic expansion
Integrity / governance 7/10 Strong alignment, but FDA compliance episode is a legitimate concern
Skin in the game 9.5/10 Very substantial founder ownership
Compensation alignment 8.5/10 Revenue/EBITDA bonus + performance options
Minority shareholder governance 6/10 Dudum controls ~87.7% of voting power

Overall, I consider Dudum an exceptionally capable founder-operator, but one whose aggressive instincts require regulatory discipline.

26. HIMS’ Balance Sheet Deserves Attention

HIMS isn’t in immediate financial distress.

At June 30 it reported approximately:

$610 million cash

plus

$231 million short-term investments.

Total liquidity from those two categories was approximately $841 million. (SEC)

But acquisitions have dramatically changed the balance sheet.

HIMS reported:

$1.37 billion of convertible senior notes

plus substantial deferred acquisition and earnout obligations.

Total contractual obligations and commitments were approximately $1.20 billion, with about $662 million payable within twelve months. (SEC)

This doesn’t mean HIMS has a balance-sheet crisis.

But the company is clearly taking more financial and integration risk than it was a few years ago.

27. Is HIMS Cheap?

This is where I disagree with anyone calling HIMS a traditional value stock.

At $28.84:

Market capitalization:

$6.73 billion

TTM revenue:

$2.58 billion

Price/Sales:

2.61×

Trailing P/E:

Not meaningful

Forward P/E:

~74×

Price/FCF:

~81× (StockAnalysis.com)

A 2.6× sales multiple for a company potentially growing 30%+ doesn’t look outrageous.

But a 74× forward P/E requires significant future earnings growth.

The market is already expecting a lot.

28. Is HIMS Less Risky Because the Stock Has Fallen?

Not necessarily.

The stock traded between approximately:

$13.74 and $65.30

over the previous 52 weeks.

HIMS’ beta is approximately:

2.42. (StockAnalysis.com)

For comparison:

Doximity:

1.21

GoodRx:

1.58

Teladoc:

2.13

LifeMD:

2.06. (StockAnalysis.com)

HIMS therefore has actually exhibited greater market volatility than every company in this comparison.

So I would definitely not call it the lowest-risk stock.

29. But Business Risk and Stock Risk Are Different

This distinction is important.

I think HIMS’ business risk is lower than LifeMD’s because HIMS has much greater scale, brand recognition, geographic diversification and product diversification.

I also prefer HIMS’ business trajectory to Teladoc’s because HIMS is growing rapidly while Teladoc is trying to stabilize declining businesses.

But HIMS’ valuation risk is considerably greater than Doximity’s.

If HIMS’ growth drops from 30%-plus to 10%-15%, a 74× forward earnings multiple could compress considerably.

Even a perfectly healthy company can produce terrible shareholder returns if investors initially pay too high a price.

30. The Bull Case

The bull thesis is extremely attractive.

Imagine HIMS eventually becoming the consumer healthcare equivalent of an Amazon or Netflix subscription relationship.

A customer might eventually receive:

doctor access

  • prescriptions
  • medication delivery
  • lab testing
  • weight management
  • preventive care
  • AI assistance
  • personalized treatment

inside one ecosystem.

If HIMS reaches its 2030 objective of at least:

$6.5 billion revenue

and

$1.3 billion adjusted EBITDA

then today’s $6.7 billion market capitalization could eventually look inexpensive. (Hims)

In that scenario, investors aren’t paying primarily for today’s earnings.

They’re purchasing a potentially much larger healthcare platform.

31. The Bear Case

The bearish scenario is equally easy to understand.

HIMS could face:

slower customer growth

higher customer-acquisition costs

GLP-1 price competition

drug manufacturers selling directly

regulatory restrictions

lower compounding economics

international acquisition problems

margin compression

equity dilution

AI healthcare regulation

very strong competitors

while investors are simultaneously paying a high earnings multiple.

That combination could produce substantial downside.

The FDA episode shows that regulatory risk isn’t theoretical. (U.S. Food and Drug Administration)

32. My Investment Ranking

If I separate the companies by what an investor is seeking, I would rank them differently.

Best growth story

1. HIMS

There is little contest.

Best profitability/valuation combination

Doximity

Far slower growth, but tremendous margins and a much lower earnings multiple.

Cheapest cash-flow story

GoodRx

But it needs to prove it can return to sustainable growth.

Turnaround speculation

Teladoc

Cheap because expectations are extremely low.

Highest-risk small-company speculation

LifeMD

Potential upside but substantially less scale and financial strength than HIMS.

33. HIMS Investment Scorecard

Category Grade
Revenue growth A+
Subscriber growth A
Addressable market A+
Brand A-
Competitive moat B+
Management intelligence A
Management energy A+
CEO shareholder alignment A
Current profitability C+
Balance-sheet risk C+
Regulatory risk C
Valuation C
Stock-price risk C
Long-term potential A

Final Verdict

I like the company more than I like the current valuation.

Hims & Hers has something relatively rare:

very high revenue growth + a recognizable consumer brand + recurring revenue + vertically integrated infrastructure + founder leadership + a huge addressable market.

Among the public direct-to-consumer digital-health companies I examined, HIMS would be my preferred company for long-term growth.

But it does not satisfy all three conditions of being:

faster growing + cheaper + lower risk.

It satisfies the first spectacularly.

Growth

Yes — HIMS wins.

Competitive advantage

Probably yes — particularly against smaller DTC competitors such as LifeMD.

Cheap P/E

No.

A roughly 74× forward P/E is considerably higher than Doximity’s ~19× and GoodRx’s ~33×. HIMS isn’t currently profitable on a trailing basis. (StockAnalysis.com)

Lowest risk

No.

The company’s growth is attractive, but regulatory uncertainty, acquisitions, margin compression, convertible debt, founder voting control and a beta of roughly 2.4 make this a relatively volatile investment.

What Would Make HIMS Particularly Attractive?

The ideal situation would be for the business to continue growing while the stock price fails to follow it.

For example:

Revenue rises

while

stock price stays flat or declines

which causes

valuation multiples to compress.

That creates the margin of safety that is currently somewhat lacking.

I would therefore categorize HIMS as:

An excellent growth company worth owning at the right valuation—not yet an obvious bargain simply because the stock has fallen substantially from its highs.

There is a strong possibility that Andrew Dudum is building one of the most important consumer healthcare companies of the next decade.

But at approximately $28.84, investors are still paying for a meaningful portion of that future success in advance.

If HIMS can simultaneously restore margins, demonstrate that the post-compounding GLP-1 model works, successfully integrate Eucalyptus, maintain 20%+ organic growth and approach its 2030 profitability targets, today’s valuation could eventually prove very reasonable.

If those things fail to happen, the stock has plenty of room for multiple compression.

That is why my overall characterization of HIMS is:

Great growth business. Strong founder. Real competitive advantages. Very large opportunity. But not yet a low-risk value stock.

One number I would watch more closely than the stock price over the next few quarters is U.S. organic revenue growth. International acquisitions can make total growth look spectacular; sustained U.S. organic growth plus recovering gross margins would give much stronger evidence that the underlying HIMS engine is still accelerating.

I can also monitor HIMS after each earnings report and flag when its valuation, growth rate, or risk profile becomes materially more attractive.

Investment